Trinity Biotech plc (TRIB), a leading developer of diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market, has seen its stock price touch a 52-week low, ...
Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc ...
Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management.
5h
MT Newswires on MSNEuropean Equities Traded in the US as American Depositary Receipts Rise in Wednesday TradingEuropean equities traded in the US as American depositary receipts were trending higher late Wednesday morning, rising 0.80% to 1,430.76 on the S&P Europe Select ADR Index. From continental Europe, ...
DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions ...
Trinity Biotech (TRIB) announced new findings from its latest pre-pivotal trial, highlighting significant improvements in first-day performance ...
Trinity announced results from its pre-pivotal clinical trial for continuous glucose monitoring system. The trial results indicated a 25% to 30% improvement in accuracy over earlier CGM sensors.
Shares of Trinity Biotech (NASDAQ:TRIB) traded sharply higher on Tuesday after the Irish MedTech reported encouraging data from a pre-pivotal clinical trial for its next-gen continuous glucose ...
Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results